Studies include Alpha, Beta, Gamma, Delta, Epsilon and Iota and it maintains antibodies for six months after the second dose
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
Substantial reduction in losses
Anti-malaria API facility will be operational in 15-18 months
Income declines marginally
Demand normalisation post the second wave contributed to the steady growth
It’s an AB-rated generic therapeutic version of Durezol
Subscribe To Our Newsletter & Stay Updated
